STOCK TITAN

Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Welcome to our dedicated news page for Aurinia Pharmaceuticals (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aurinia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aurinia Pharmaceuticals's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
-
Rhea-AI Summary
A significant shareholder of Aurinia Pharmaceuticals, MKT Capital, supports Iljin's concerns about the board's inability to drive value. They recommend withholding support for Chairman Dr. George Milne and Compensation Committee Chair Joseph Hagan at the upcoming Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
Rhea-AI Summary
Aurinia Pharmaceuticals has received marketing authorization from Swissmedic for LUPKYNIS to treat lupus nephritis. The approval is based on positive results from clinical studies, showing superior response rates and stable kidney function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
Aurinia Pharmaceuticals Inc

Nasdaq:AUPH

AUPH Rankings

AUPH Stock Data

723.09M
131.74M
7.45%
38.61%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Victoria

About AUPH

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.